Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation (Q43981278)

28 November 2017

Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation (English)

1 reference

28 November 2017

1 reference

Jeffrey Cummings

1

1 reference

28 November 2017

Gary Boyd

2

1 reference

28 November 2017

Brian T Ethell

3

1 reference

28 November 2017

Janet S Macpherson

4

1 reference

28 November 2017

Brian Burchell

5

1 reference

28 November 2017

John F Smyth

6

1 reference

28 November 2017

Duncan I Jodrell

7

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

28 November 2017

Biochemical Pharmacology

1 reference

28 November 2017

63

1 reference

28 November 2017

4

1 reference

28 November 2017

607-613

1 reference

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

Clinical pharmacology of camptothecins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

New directions in the treatment of colorectal cancer: a look to the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

Diversity of DNA topoisomerases I and inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

Topoisomerase I poisons and suppressors as anticancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

Topoisomerase I inhibitors: selectivity and cellular resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900812-7

10.1016/S0006-2952(01)00812-7

7 January 2021

Identifiers

DOI

1 reference

28 November 2017

1 reference